| 摘要 |
Diagnostic and therapeutic compositions and methods which target a melanoma associated delayed early response (MADER) gene and its expression products are described. Specifically, the invention relates to the production, characterization and use of monoclonal antibodies capable of specifically binding to an approximately 55 kD MADER protein which is overexpressed in human malignant melanomas and other human cancerous tissue. Such antibodies are able to detect overexpressed MADER in cultured cells and frozen or paraffin-embedded sections of human biopsy material. The MADER protein, fragments or analogs thereof, or its gene in a vector suitable for a DNA vaccine, are employed as anti-cancer immunogens in the immunotherapeutic treatment of malignant melanoma and other cancerous conditions. Similarly, MADER polynucleotides are used herein in various cytological methods for detecting cells which overexpress MADER. MADER mRNAs are used as targets in antisense and ribozyme therapies directed at inhibiting the expression of MADER in a treated subject. |
